SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is surging following the FDA approval of VYKAT XR, the first treatment for hyperphagia in Prader-Willi syndrome, fueling community discussion around its blockbuster potential and possible future acquisition. Investors are closely monitoring the stock's transition from a clinical-stage development play to a commercial-stage entity, with analysts aggressively revising price targets upward to reflect the de-risked profile.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is maintaining strong momentum as the community rallies around its unique 'culture-first' brand identity ahead of key industry events. Investors are actively discussing its long-term potential, citing consistent organic growth and a commitment to advocacy that resonates with supporters beyond traditional market metrics.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as traders closely watch the stock's relative strength and consolidation patterns amid a broader market pullback. Market participants are actively discussing the impact of recent subscription price increases on revenue growth while monitoring key technical resistance levels that could trigger a potential breakout.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently experiencing intense volatility and downward pressure as investors grow increasingly frustrated with leadership's communication and the lack of a major partnership or buyout announcement. The community is actively debating the impact of recent R&D leadership changes and speculative proxy pressure, while many remain focused on the potential value of the Matrix-M platform to spark a significant recovery.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind $BUTTCOIN as a satirical movement aimed at disrupting the traditional financial system, with community members actively promoting it as the next major meme cycle. The conversation is driven by intense speculation and viral narratives, with supporters urging others to join the movement to flip Bitcoin while others emphasize the coin's role as a lighthearted commentary on market volatility.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending due to a definitive agreement to acquire Soleno Therapeutics for $53 per share in an all-cash deal valued at approximately $2.9 billion. Community sentiment is mixed, with some investors debating the valuation and strategic rationale of the acquisition, while others are pressuring management to accelerate pipeline development or consider selling the company to unlock shareholder value.

ProShares Trust - ProShares K-1 Free Crude Oil ETF

ProShares K-1 Free Crude Oil Strategy ETF

ProShares K-1 Free Crude Oil Strategy ETF is attracting attention as the broader energy sector faces significant volatility driven by a growing global crude supply glut and shifting geopolitical dynamics, including potential ceasefire developments and diplomatic negotiations. Market participants are actively debating the sustainability of current oil price levels, with many community members focusing on technical indicators, inventory data, and the potential impact of geopolitical cooling on long-standing supply-shock narratives.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased investor attention as a leading example of post-quantum cryptography in a recent Google research paper, bolstering the community's long-term thesis on its security standards. While some users are actively debating potential institutional utility and the impact of the foundation's shift to the U.S., community discussions remain heavily polarized between long-term proponents betting on technical robustness and critics focused on recent price trends.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is attracting significant investor attention as defense and technology sectors prioritize domestic rare earth magnet production to secure supply chains against potential geopolitical disruptions. The community is actively discussing the stock's strategic role in national security and potential price catalysts following major government partnership developments.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

ProShares Ultra Bloomberg Crude Oil (UCO) is trending as traders closely monitor escalating geopolitical tensions in the Middle East and ongoing instability around the Strait of Hormuz. Community discussion is heavily focused on conflicting reports regarding potential ceasefire negotiations and the sustainability of oil price spikes, with many investors actively debating the validity of diplomatic headlines against the backdrop of supply constraints and military maneuvers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of BrainStorm Cell Therapeutics slipped in after-hours trading Thursday after the company said&nbsp;it has been removed from the Nasdaq Capital Market for falling short of minimum equity requirements.The stock will stop trading on Nasdaq when&nbsp;the&nbsp;markets open Friday.&nbsp;Brainstorm Cell’s stock plunged 42.7% in after-hours trading on Thursday, falling to $0.67, following a 2.5% dip during the regular session.The company said it has received approval to shift its listing to the OTCQB Venture Market, where it will continue trading under the same ticker.“While this delisting is a difficult outcome, it does not change our core mission or our dedication to the ALS community,” said CEO Chaim Lebovits. “Our move to the OTCQB ensures trading continuity and allows us to maintain focus on advancing NurOwn.”NurOwn is BrainStorm’s experimental cell therapy for ALS, a progressive disease that steadily weakens muscles and shortens lives.&nbsp;The company is preparing to launch a pivotal Phase 3b trial, designed in coordination with the FDA under a Special Protocol Assessment agreement.In June, BrainStorm released new survival data from 10 ALS patients who received NurOwn through its Expanded Access Program.The company reported that 90% of those patients survived more than five years from symptom onset, marking a significant contrast to the roughly 10% survival rate reported in the general ALS population.&nbsp;The median survival was 6.8 years, with the only death attributed to elective euthanasia.To support the upcoming trial, BrainStorm recently entered a manufacturing agreement with Minaris Advanced Therapies, a U.S.-based contract development and manufacturing organization.&nbsp;It has also partnered with Israel-based Pluri to expand clinical supply capabilities.The company stated that the Nasdaq delisting will not affect its business operations, R&amp;D activities, or its commitment to shareholders.On Stocktwits, retail sentiment for Brainstorm was ‘bullish’ amid ‘high’ message volume.One user said that BrainStorm can possibly tap the at-the-market (ATM) facility to fund its upcoming trial, citing the stock’s rebound.<stembedurl>https://stocktwits.com/steven_glandsberg/message/621369650</stembedurl>Another user saw the dip as a buying opportunity, calling it a “good buy time.”<stembedurl>https://stocktwits.com/bigdave100/message/621361783</stembedurl><a href="https://stocktwits.com/symbol/BCLI">Brainstorm’s stock</a> has declined 45.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a man walking in front of the Nasdaq building at Times Square in New York. (Photo by John Smith/VIEWpress)

BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time'

Shares of BrainStorm Cell Therapeutics slipped in after-hours trading Thursday after the company said it has been removed from the Nasdaq Capital Market for falling short of minimum equity requirements.

Equity

The company plans to move its shares to the OTCQB market and says the delisting won't impact its ALS research or upcoming Phase 3b trial. 

BrainStorm Cell Therapeutics saw rising retail chatter Monday when it obtained FDA clearance for Phase 3b clinical trials of NurOwn, its amyotrophic lateral sclerosis (ALS) stem cell therapy candidate.Through a Special Protocol Assessment (SPA), the FDA confirmed that the study design and statistical methodology meet regulatory standards required for future BLAs.The company’s shares closed up 3.03% at $1.36 on Monday but slipped 12.54% to $1.19 in after-hours trading.BrainStorm CEO Chaim Lebovits said the FDA approval allows the company to commence operations at clinical sites while it pursues funding through multiple sources, such as non-dilutive grants.The clinical Phase 3b trial aims to enroll around 200 ALS patients from leading academic institutions.&nbsp;A 24-week double-blind placebo-controlled trial will initiate the study before moving into a 24-week open-label extension, during which all patients receive NurOwn.&nbsp;Researchers will assess the primary outcome by measuring the change in ALSFRS-R scores from baseline to week 24.Completing Phase 3 research allows NurOwn to hold Orphan Drug status concurrently in the United States and the European Union.&nbsp;Meanwhile, the U.S. Patent Office approved BrainStorm's intellectual property rights to develop an allogeneic exosome-based platform.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 31,000% surge in 24-hour message volume.Some traders pointed to the company’s pursuit of private grants or potential partnerships, with names like Johns Hopkins University and Pfizer mentioned as speculative collaborators, as key bullish drivers.<stembedurl>https://stocktwits.com/Whealthy/message/615149075</stembedurl>Others noted the heavy intraday volume, which reached 58 million shares, expressing frustration over the lack of price movement during regular hours.&nbsp;Still, optimism remained for a possible after-hours push or improved action in the following session, with hopes for reduced resistance ahead.<stembedurl>https://stocktwits.com/Kojak3/message/615151221</stembedurl>The stock has declined 36.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Physical Therapy for the Elderly Caused by Amyotrophic Lateral Sclerosis. Asian home nurse helping a senior woman while doing physical therapy on her patient outdoors. Photo credit: Getty Images

Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours

BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Brainstorm Cell Therapeutics, Inc.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

BCLI
Brainstorm Cell Therapeutics, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BCLI News

BCLIBrainstorm Cell Therapeutics, Inc.